Antithrombotic therapy during percutaneous coronary intervention: The seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

Popma, Jeffrey J.; Berger, PB; Ohman, E. Magnus; Harrington, RA; Grines, C.L.; Weitz, Jeffrey I.

doi:10.1016/j.accreview.2004.12.107

Cited by 68 publications

(107 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There was a trend toward a higher incidence of major bleeding in the A+W group. This observation was also noted in other studies and could be related to the intensity of treatment with warfarin (9,22). Indeed, 66% of patients with major bleeding in the A+W group and 50% in the CTT group had INR values well above the therapeutic range.…”

Section: Discussionsupporting

confidence: 83%

“…More recently, long-term, dual antiplatelet therapy using ASA and clopidogrel has shown advantages in managing patients with ACS, whether in association with percutaneus coronary intervention (PCI) or not (5)(6)(7)(8). This has evolved into the current guidelines for the antithrombotic treatment of patients with ACS (9)(10)(11). However, in contemporary clinical practice, cardiologists are faced with an aging population with more comorbidities.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Safety of the cardiac triple therapy: The experience of the Quebec Heart Institute

Brulotte¹,

Sénéchal²,

Poirier³

et al. 2007

Canadian Journal of Cardiology

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 83%

mentioning

confidence: 99%

Safety of the cardiac triple therapy: The experience of the Quebec Heart Institute

Brulotte¹,

Sénéchal²,

Poirier³

et al. 2007

Canadian Journal of Cardiology

View full text Add to dashboard Cite

“…10,[21][22][23][24] In cardiogenic shock, high-dose dopamine therapy has to be maintained for blood recirculation; if it is not, the opportunity to save the patient might be lost. Consequently, the authors advocate early application of IABP.…”

Section: -17mentioning

confidence: 99%

Early application of an intra-aortic balloon pump in patients with ST-segment elevation acute myocardial infarction scheduled for elective percutaneous coronary intervention

Dong

Liu

et al. 2013

J Int Med Res

View full text Add to dashboard Cite

Objective: This study evaluated the effect of early application of intra-aortic balloon pump (IABP) counterpulsation in patients with ST-segment elevation acute myocardial infarction (STEMI), scheduled for elective percutaneous coronary intervention (PCI). Methods: Patients who had experienced STEMI for 12-72 h received (IABP group) or did not receive (control group) IABP counterpulsation for 3-5 days before PCI. Results: One hundred patients were included. Frequencies of infarct-related artery thrombolysis in acute myocardial infarction (TIMI) flow rate classes 0, I and II in the IABP group (11.5, 1.9 and 7.7%, respectively) were significantly lower than in the control group (29.1, 14.6 and 22.9%, respectively) before PCI. After PCI, the frequency of TIMI class III flow rate in the IABP group (96.2%) was significantly higher than that in the control group (81.3%). Four weeks after PCI, the left ventricular ejection fraction (LVEF) was significantly higher, and the incidence of major cardiac events was significantly lower, in the IABP group compared with the control group. Conclusions: Early use of IABP counterpulsation in STEMI patients scheduled for PCI was effective, with a favourable safety profile. IABP counterpulsation reduced the incidence of major adverse cardiac events and improved LVEF. However, IABP devices must be used at an early stage, to obtain optimal results.

show abstract

“…There is no doubt that cessation of antiplatelet therapy in patients with a recent coronary stent carries a significant risk [14]. In addition, one French study suggests that recent withdrawal of this therapy may be harmful in patients with coronary artery disease.…”

Section: Risk Of Antiplatelet Withdrawal and Bridging Therapymentioning

confidence: 99%

The Role of Anticoagulant Therapy During Prostate Biopsy

Zaman¹,

Bach²,

Kumar³

et al. 2011

Prostate Biopsy

View full text Add to dashboard Cite

Antithrombotic therapy during percutaneous coronary intervention: The seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

Cited by 68 publications

References 0 publications

Safety of the cardiac triple therapy: The experience of the Quebec Heart Institute

Safety of the cardiac triple therapy: The experience of the Quebec Heart Institute

Early application of an intra-aortic balloon pump in patients with ST-segment elevation acute myocardial infarction scheduled for elective percutaneous coronary intervention

The Role of Anticoagulant Therapy During Prostate Biopsy

Contact Info

Product

Resources

About